Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Navidea Biopharmaceuticals Inc announces approval of Lymphoseek (technetium Tc 99m tilmanocept) Injection from FDA


Friday, 13 Jun 2014 12:26pm EDT 

Navidea Biopharmaceuticals Inc:Says that the U.S. Food and Drug Administration (FDA) approves Supplemental New Drug Application (sNDA) for expanded use of Lymphoseek(technetium Tc 99m tilmanocept) Injection.Says this Injection is indicated for guiding sentinel lymph node (SLN) biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity. 

Company Quote

1.68
0.03 +1.82%
27 Mar 2015